2020, Number 4
<< Back Next >>
Rev cubana med 2020; 59 (4)
Characterization of the clinical course of kidney transplantation in patients with positive hepatitis C virus
Borroto DG
Language: Spanish
References: 40
Page: 1-14
PDF size: 402.63 Kb.
ABSTRACT
Introduction:
Hepatitis C virus infection is a common event in kidney transplant recipients that has dragged it along since their stay in hemodialysis treatments prior to implantation. Positivity to virus C has been associated with an unfavorable evolution after transplantation, due to higher frequency of clinical, metabolic and immunological complications that negatively affect both graft and patient survival.
Objectives:
To describe the clinical evolution of kidney transplant patients with positive hepatitis C virus and to determine the evolution of this group of patients according to demographic, clinical and survival variables.
Method:
An analytical, cross-sectional, retrospective study in kidney transplant patients at Hermanos Ameijeiras Hospital was carried out from 2005 to 2017. This study excluded children under 15 years of age, re-transplants, double and combined transplants or when it was not possible to gather the information. The variables chosen among patients who arrive at transplantation with positive serology for virus C (positive HCV) were compared with negative HCV.
Results:
One hundred and fifty six patients were the total, 65% (102) were HVC positive, no differences were found between groups in terms of age and sex of recipients and donors, nor in the immunosuppressive treatment used. The living donor was less used in positive HVC where more patients with polycystic kidney disease were found. Acute tubular necrosis (ATN) and rejection were more frequent in positive HVC, the former being statistically significant, p = 0.0421, proteinuria, p = 0.041, elevation was also significantly more frequent in the positive HVC group of liver enzymes, p = 0.047 and post-transplant diabetes, p = 0.047. Graft and patient survival was lower in positive HCV.
Conclusions:
In this study, hepatitis C virus has negative impact on the evolution of the graft and favors the appearance of some clinical complications, which undoubtedly could influence a shorter life expectancy for both the graft and the patient.
REFERENCES
Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nature Rev Nephrol., 2015;11: 172-182
Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1-13. https://doi.org//10.7326/M15-0785
S. Lens, M. Gambato, M.C. Londono, X. Forns. Interferon-free regimens in the liver-transplant setting. Semin Liver Dis. 2014;34:58-71.
Fabrizi F, Messa P, Martin P. Update to hepatitis C review. Kidney Int. 2014;85:1236-39.
Corell A. Immunosuppression induced by hepatitis C virus infection reduces acute renal transplant rejection. Lancet. 2015;346: 497-98.
Goodkin DA, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni RL. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol. 2017;12:287-97. https://doi.org//10.2215/CJN.07940716
Goldberg DS, Blumberg E, McCauley M, Abt P, Levine M. Improv- ing organ utilization to help overcome the tragedies of the opioid epidemic. Am J Transplant. 2016;16:2836-41. https://doi.org//10.1111/ajt.13971
Cruzado JM, Bestard O, Grinyo JM. Impact of extrahepatic complications (diabetes and glomerulonephritis) associated with hepatitis C virus infection after renal transplantation. Contrib. Nephrol. 2012;176:108-16.
Eckman MH, Woodle ES, Thakar CV, Paterno F, Sherman KE. Transplanting hepatitis C virus-infected versus uninfected kidneys into hepatitis C virus-infected recipients. A cost-effectiveness analysis. Ann Intern Med. 2018;169:214-23. https://doi.org//10.7326/M17-3088
Baid Agrawal S. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allografts recipients. J. Am. Soc. Nephrol. 2013;10:146-53.
Baid Agrawal S. Hepatitis C virus infection and kidney transplantation in 2014. What's new? Am. J. Transplant. 2014;14:2206-20.
Fabrizi F. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am. J. Transplant. 2015;5:1452-61.
Xia Y. Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses. Am. J. Transplant. 2014;14:2037-47.
Gallegos Orozco JF, Kim R, Thiesset HF, Hatch J, Lynch K, Chaly T, et al. Early results of pilot study using hepatitis C Virus (HCV) Positive Kidneys to Transplant HCV Infected Patients with End-Stage Renal Disease Allowing for Successful Interferon-Free Direct Acting Antiviral Therapy after Transplantation. Cureus 2016;8(11):e890. https://doi.org/10.7759/cureus.890
Gentil MA. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol. Dial. Transplant. 2017;94:2455-60.
Adinolfi L. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J. Gastroenterol. 2014;20:3410-17.
Kiberd BA, Doucette K, Vinson AJ, Tennankore KK. Hepatitis C virus-infected kidney waitlist patients: treat now or treat later? Am J Transplant. 2018. https://doi.org//10.1111/ajt.14891
Goldberg DS, Abt PL, Blumberg EA, Van Deerlin VM, Levine M, Reddy KR, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients [Letter]. N Engl J Med. 2017;376:2394-5. https://doi.org//10.1056/NEJMc1705221
American Diabetes Association. Diagnosis and clasification of diabetes mellitus. Diabetes Care 2004;27(S 1):5-10.
Millet Torres D, Curbelo Rodríguez L, Ávila Riopedre F, Benítez Méndez M, Prieto García F. Evolución general de receptores de trasplante renal con hepatitis C en el hospital provincial de Camagüey, Cuba. Nefrología. 2015;35(5):509-16.
Yu TM, Lin CC, Shu KH, Chuang YW, Huang ST, Chen CH, et al. Increased risk of hepatic complications in kidney transplantation with chronic virus hepatitis infection: A nationwide population-based cohort study. Sci Rep. Transplant. 2010;10:2453-62. https://doi.org/10.1038/srep21312.2
Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C Virus Infection. PLoS ONE. 2016;11(7):e0158431. https://doi.org/10.1371/journal.pone.0158431
Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C Virus Infection. PLoS ONE. 2016;11(7):e0158431. https://doi.org/10.1371/journal.pone.0158431
Diekman F, Campistol JM. Practical considerations for the use of immunosuppression. Transplant research. 2015,4(S1):5.
Lee M, Langone AJ. Drugs in development for the prophylaxis of rejection in kidney transplant recipient. Dovepress. 2015;7:59-69.
Niavdet P. Living donor kidney transplantation in patients with nephropathies. Nature Rev Nephrol. 2010,6:736-40.
Andrés A. Indicaciones y contraindicaciones del trasplante renal de donante vivo en Recomendaciones de la SEN para el trasplante renal de donante vivo. Nefrología. 2010;30(S-2):30-37.
Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to non infected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168:533-40. https://doi.org/10.7326/M17-2871
Farakash E, Colvin R. Diagnostic challenges in chronic antibody mediated rejection. Nat Rev Nephrol. 2012,8:255-57.
Scornik JC, Guerra G, Schold JD, Srinivas TR, Dragun D, Meier-Kriesche HU. Value of postrasplante antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant. 2007;7:1808-14.
Kowalski RJ, Post DR, Mannon R Bal. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663-8.
Sánchez A, Guirado L, Ramos D. Prognostic, significance and diagnosis of proteinuria in renal transplant. Transplant Rev. 2012,26:30-35.
Suárez M, Cosio FG. Causas y consecuencias de la proteinuria después del trasplante renal. Nefrología. 2011,31(4):404-14.
Melilli E, Cruzado MJ, Bestard O, Hernández D. Mechanism and risk factor for development of proteinuria after kidney transplantation. Transplant Rev. 2012,26:14-19.
Hernández D, Torres A. Alteraciones del metabolismo de la glucosa tras el trasplante renal: análisis de la evidencia. Nefrología Sup Ext. 2010;1(2):3-10.
Sharif A, Baboolal K. Complications associated with new-onset diabetes after kidney transplantation. Nat. Rev. Nephrol. 2014;8:34-42.
Borroto Díaz G, Barceló Acosta M. Complicaciones metabólicas tras el trasplante renal. Rev Cubana Aliment Nutr. 2014;24(2):280-303.
Borroto Días G. Exceso de peso, resistencia a la insulina, y función renal en el paciente con un injerto renal. Rev Cubana de Aliment y Nutr. 2014;24(2):112-22.
Borroto Díaz G; Guerra BG; Guerrero DC; Infante SA; González ÁM. Impacto del virus de la hepatitis C en las complicaciones inmediatas y los trastornos metabólicos glucémicos del trasplante renal. Rev Cubana de Medicina. 2009;34:124-27.
Singh N, Neidlinger N, Djamali A, Leverson G, Voss B, Sollinger HW, Pirsch JD. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant. 2012;26:684-69.